Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.

No Thumbnail Available
Authors
Tikhonova, I. A.
Huxley, N.
Snowsill, T.
Crathorne, L.
Varley-Campbell, J. L.
Napier, Mark
Hoyle, M.
Journal
PharmacoEconomics
Type
Journal Article
Publisher
Springer
Rights
Archived with thanks to PharmacoEconomics
Combination therapies with cetuximab (Erbitux®; Merck Serono UK Ltd) and panitumumab (Vectibix®; Amgen UK Ltd) are shown to be less effective in adults with metastatic colorectal cancer who have mutations in exons 2, 3 and 4 of KRAS and NRAS oncogenes from the rat sarcoma (RAS) family.
Citation
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. 2018 Pharmacoeconomics
Note